Don’t Buy Canopy Growth (TSX:WEED) Stock: These Pot Stocks Take the Cake

The market loves the partnership between Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and Constellation Brands, Inc. (NYSE:STZ), but there are better cannabis stocks to trust with your money.

edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is one of the most loved cannabis stocks on the market. With a valuation of $8.6 billion, it’s also one of the largest.

One of the biggest reasons for Canopy’s vaunted position is Constellation Brands, Inc. (NYSE:STZ).

Constellation is a highly successful consumer brand company. With the rights to globally recognized brands like Modelo and Corona, Constellation is the largest beer importer in the U.S., generating more than $8 billion in annual sales.

Last year, Constellation invested more than $4 billion into Canopy, forming an exclusive partnership. With the influence, expertise, and financial backing of Constellation, the market fell in love with Canopy. At one point, it had a $20 billion market cap.

The Canopy-Constellation partnership is powerful, but that doesn’t make it the best place to put your money. In fact, if you want to bet on the benefits of that partnership, there are two superior options in which to invest.

Go bigger

If you want to invest in a cannabis stock because it has a high-powered partner, there’s no better option than Cronos Group Inc (TSX:CRON)(NYSE:CRON).

Pot is a highly regulated market. Navigating these regulations is extraordinarily difficult, especially if you want to be a global player. Every country has different rules.

In the U.S., the largest marijuana market in the world, regulations vary by state, and even by city.

When it comes to navigating complex, ever-evolving regulatory environments, Altria Group Inc (NYSE:MO) takes the cake. This $100 billion tobacco behemoth has proven an ability to dominate the market for controlled substances. If you invested in Altria stock back in 1979, you would have made 2,000 times your original investment.

This year, Altria took a $1.8 billion position in Cronos. Now Cronos can leverage the influence, connections, expertise, and financial backing of one of the most powerful tobacco companies on the planet. There really isn’t a more valuable partner to have.

Go wider

Hexo Corp. (TSX:HEXO)(NYSE:HEXO) realizes the value of a powerful partner, which is why it’s taking a different approach — one that will allow it to secure dozens of valuable partners.

Rather than simply growing pot and selling it on the open market or investing heavily to build its own cannabis brands, HEXO is partnering with existing companies to co-create products.

For example, it has a deal with Molson Coors Canada Inc. that will launch a cannabis-infused beverage in Canada this month.

Ask yourself which one is more likely to succeed: a Molson-branded beverage or a new beverage from an unknown start-up?

HEXO is betting that partnering with existing brands will give it immediate sales traction and customer loyalty. Its cannabis infrastructure is purposefully set up so that any company can co-create products alongside HEXO.

In 2020, expect the company to add new partners in emerging verticals like cosmetics and sleep aids, although consumables will still represent a big opportunity.

Investing in the Canopy-Constellation partnership bets that cannabis beverages will be a huge market. Why not invest in HEXO, then, which is capable of attracting dozens of simultaneous beverage partners?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands, HEXO., and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »